AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IMTX · NASDAQ · Biotechnology

Immatics (IMTX)

Develops PRAME-focused cancer therapies with cell therapy and TCR bispecific programs.

$8.87

After hours+0.00 (+0.06%)

At close$8.87(+1.66%)

In millions of USD, except per-share figures · converted from EUR at the latest rate

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	7	18	35	21	58	64	21	5	6	23	9	10
Cost of revenue	35	0	0	0	0	0	0	0	0	0	0	0
Gross profit	−28	18	35	21	58	64	21	5	6	23	9	10
	45	50	50	52	57	63	62	66	68	67	84	87
Research & development	35	38	37	40	45	48	48	52	54	57	68	71
	10	12	13	12	13	15	14	15	15	16	17	16
General & administrative	10	12	13	12	13	15	14	15	15	16	17	16
Other expenses	0	0	0	0	0	0	0	0	0	−5	0	0
Operating income	−38	−32	−15	−30	1	1	−41	−61	−63	−45	−76	−77
	8	2	13	10	−3	49	−6	−21	5	4	10	5
Interest income	5	6	7	7	6	8	6	5	4	4	4	4
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−8	−2	−14	−10	3	−49	6	21	−5	−4	−10	−5
Income before tax	−30	−30	−2	−20	−3	50	−47	−82	−58	−41	−66	−72
Income tax expense	0	0	1	0	7	−2	−1	−1	0	0	0	0
Net income from continuing operations	−30	−30	−3	−21	−10	51	−46	−81	−58	−41	−66	−72
Net income	−30	−30	−3	−21	−10	51	−46	−81	−58	−41	−66	−72
EPS, basic	−$0.37	−$0.35	−$0.02	−$0.19	−$0.09	$0.53	−$0.38	−$0.66	−$0.48	−$0.32	−$0.49	−$0.53
EPS, diluted	−$0.37	−$0.35	−$0.03	−$0.19	−$0.13	$0.53	−$0.38	−$0.66	−$0.48	−$0.32	−$0.49	−$0.53
Weighted average shares, basic	83	85	99	103	106	106	122	122	122	126	135	137
Weighted average shares, diluted	83	85	106	103	110	107	122	122	122	126	135	137
EBITDA	−28	−28	2	−17	1	53	−43	−78	−54	−37	−63	−68
Depreciation & amortization	2	2	3	4	3	4	4	3	4	4	3	3
EBIT	−30	−30	−2	−20	−2	50	−46	−81	−58	−40	−66	−72